An acidic oligopeptide displayed on AAV2 improves axial muscle tropism after systemic delivery
Authors:
- Ni-Chung LeeNLNi-Chung Lee
- Darin J FalkDFDarin J Falk
- Barry J ByrneBBBarry J Byrne
- Thomas J ConlonTCThomas J Conlon
- Nathalie ClementNCNathalie Clement
- Stacy PorvasnikSPStacy Porvasnik
- Marda L JorgensenMJMarda L Jorgensen
- Mark PotterMPMark Potter
- Kirsten E ErgerKEKirsten E Erger
- Rachael WatsonRWRachael Watson
- Steven C GhivizzaniSGSteven C Ghivizzani
- Hung-Chuan ChiuHCHung-Chuan Chiu
Open Access
- 18 June 2012
- journal article
- research article
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 10 (1) , 3
Abstract
The appropriate tropism of adeno-associated virus (AAV) vectors that are systemically injected is crucial for successful gene therapy when local injection is not practical. Acidic oligopeptides have been shown to enhance drug delivery to bones. In this study six-L aspartic acids (D6) were inserted into the AAV2 capsid protein sequence between amino acid residues 587 and 588. 129SVE mice were injected with double-stranded wild-type- (WT-) or D6-AAV2 mCherry expression vectors (3.24 x 1010 vg per animal) via the superficial temporal vein within 24 hours of birth. Fluorescence microscopy and quantitative polymerase chain reaction confirmed higher levels of mCherry expression in the paraspinal and gluteus muscles in the D6-AAV2 injected mice. The results revealed that although D6-AAV2 was less efficient in the transduction of immortalized cells stronger mCherry signals were detected over the spine and pelvis by live imaging in the D6-AAV2-injected mice than were detected in the WT-AAV2-injected mice. In addition, D6-AAV2 lost the liver tropism observed for WT-AAV2. An acidic oligopeptide displayed on AAV2 improves axial muscle tropism and decreases liver tropism after systemic delivery. This modification should be useful in creating AAV vectors that are suitable for gene therapy for diseases involving the proximal muscles.Keywords
This publication has 22 references indexed in Scilit:
- Rescue of Severe Infantile Hypophosphatasia Mice by AAV-Mediated Sustained Expression of Soluble Alkaline PhosphataseHuman Gene Therapy, 2011
- The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liverBlood, 2011
- The AAV9 receptor and its modification to improve in vivo lung gene transfer in miceJournal of Clinical Investigation, 2011
- Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard MaterialHuman Gene Therapy, 2010
- RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapyThe Journal of Gene Medicine, 2010
- Enhancement of Drug Delivery: Enzyme-replacement Therapy for Murine Morquio A SyndromeMolecular Therapy, 2010
- A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic deliveryGene Therapy, 2009
- Genetic Modification of Adeno-Associated Viral Vector Type 2 Capsid Enhances Gene Transfer Efficiency in Polarized Human Airway Epithelial CellsHuman Gene Therapy, 2008
- Enhancement of drug delivery to bone: Characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptideMolecular Genetics and Metabolism, 2006
- Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus CapsidsMolecular Therapy, 2001